【摘要】 目的:比较齐拉西酮与利培酮治疗女性精神分裂症的疗效及安全性。方法:将72例女性精神分裂症患者随机分为齐拉西酮组[(131.6±10.3)mg/d]36例,利培酮组[(5.9±1.3)mg/d]36例,疗程均为12周,采用阳性及阴性症状量表(PANSS),治疗中需处理的不良反应症状量表(TESS),在治疗前及治疗第2、4、8、12周末分别评定疗效和不良反应。结果:治疗第2周末开始,两组PANSS评分较入组时均显著降低,差异有统计学意义(P<0.05);治疗结束时,齐拉西酮组、利培酮组显效率及临床总有效率分别为50.0%、77.8%与47.3%、75.0%,两组疗效比较差异无统计学意义(P>0.05)。不良反应的发生率齐拉西酮组为47.2%(17/36)、利培酮组为52.8%(19/36),两组比较,差异无统计学意义(P>0.05)。但齐拉西酮组锥体外系反应、体重增加、血脂增高、高泌乳素的发生率明显低于利培酮组,差异有统计学意义(P<0.05)。结论:齐拉西酮治疗女性精神分裂症疗效好,不良反应轻微。更多还原

【Abstract】 Objective:To compare the efficacy and safety of Ziprasidone and Risperidone in the treatment of female patients with schizophrenia.Methods:A total of 72 female patients were randomly assigned to Ziprasidone group(n=36) and Risperidone group(n=36),and received Ziprasidone(131.6±10.3) mg/d and Risperidone(5.9±1.3) mg/d treatment for 12 weeks respectively.The efficacy and adverse reaction were assessed with the Positive and Negative Syndrome Sale(PANSS),the Treatment Emergency Syndrome Scale(TESS) after the tveatment of 2,4,8,12 week.Results:The PANSS scores significantly decreased compared with the baseline sores in both groups since the second week(P<0.05);the marked improvement rate was 50.0% and the total clinical effective rate was 77.8% in Ziprasidone group while 47.3% and 75.0% in Risperidone group,there were not significant differences between two groups(P>0.05).There were similar rates of side effects between both groups(P>0.05),Ziprasidone group was 47.2%(17/36) and Risperidone group was 52.8%(19/36)(P>0.05).But the incidence of extrapyramidal symptoms,weight gain,high blood fat,hyperprolactin were significantly lower in the Ziprasidone group than those in the Risperidone group(P<0.05).Conclusion:The results suggest Ziprasidone be of good efficacy and less adverse effects in the treatment of female patiens with schizophrenia.更多还原